tirzepatide pills vs injections Compounded vs. Zepbound – Forbes Health Benefits of Tirzepatide Injections |

Once your physician reviews your results and clears candidacy, your first dose can usually be administered within the same week

Ridha, S.G

Volkow, Claus Thorn Ekstrm, Gitte Moos Knudsen, Tina Vilsbll, and Anders Fink-Jensen

Key Highlights Three once-monthly injections achieved placebo-adjusted weight loss of up to 6.3% at Week 12, increasing to 7.5% at Week 16 Weight loss maintained up to 4 months after the final dose, supporting once-quarterly maintenance therapy potential No weekly lead-in dosing required, differentiating ASC30 from many current GLP-1 regimens Safety profile consistent with the GLP-1 class, with mild-to-moderate adverse events and no discontinuations Why It Matters: Convenience advantage: Monthly or quarterly dosing could significantly improve adherence vs weekly GLP-1 injections Small-molecule innovation: ASC30 is a GLP-1 biased small molecule, enabling both oral and injectable formulations Platform validation: Supports Ascletis Ultra-Long-Acting Platform (ULAP) for developing long-duration metabolic therapies Key Takeaway: ASC30 highlights the next frontier in obesity therapeuticsultra-long-acting incretin therapies